Vasculitis & polymyalgia rheumatica
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients
Authors' conclusion
CRP gene rs1205 and rs3093068 polymorphisms influence GCA susceptibility and its outcomes.
Study context
- Population
- Northern Italian patients with biopsy-proven giant cell arteritis (GCA) (Reggio Emilia) and healthy controls
- Participants
- 170 vs 200
- Comparison
- Biopsy-proven GCA vs healthy controls, C-reactive protein (CRP) gene polymorphisms rs1205 and rs3093068
- GCAn = 170
- Controlsn = 200reference
- Outcome
- Associations of CRP gene polymorphisms rs1205 (3872C>T) and rs3093068 (4741G>C) with GCA susceptibility
Main finding
As reported in the abstract
GCA susceptibility by CRP genotype
GCA vs ControlsEstimate (95% CI)P value
More frequent in GCA
OR, rs1205 T/T homozygosity 2.28(1.1–4.8)
P = 0.006Less frequent in GCA
OR, rs3093068 allele C 0.39(0.24–0.73)
P = 0.002Less frequent in GCA
OR, rs3093068 C allele carriers (C/C+C/G) 0.35(0.17–0.70)
P = 0.002Observational data: associations, not effects.
Further findings
rs3093068 C allele carriers vs Non-carriers
CRP at diagnosis, GCA patients by rs3093068 allele C carriage · significantly higher in carriers
P = 0.007
rs1205 T/T vs rs1205 C allele carriers
| Outcome | rs1205 T/T | rs1205 C allele carriers | OR (CI) | P value | |
|---|---|---|---|---|---|
| Eosinophil infiltration of temporal artery wall, GCA patients by rs1205 genotype | 21.4% | 6.0% | 4.28 (1.31–13.98) | P = 0.010 | |
| 0.050.21520Odds ratio (log scale) |
Baseline clinical manifestations
- No significant associations with the two polymorphisms
Glucocorticoid (GC) treatment and remission, rs1205 allele T carriers
- Lower GC treatment duration (p=0.041)
- Lower cumulative total GC dose (p=0.017)
- Higher prevalence of long-term remission (p=0.024)
Original publication
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients. Clin Exp Rheumatol. Published 5 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →